Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis Files NDA for Acromegaly Treatment Pasireotide in Japan
August 3, 2015
- Bayer Yakuhin Files Nexavar to Expand Indication for Thyroid Cancer
August 3, 2015
- Otsuka Holdings Increases Forecasts for 1st Half of FY2015
August 3, 2015
- Wholesalers Must Ponder Use of Reps for New Business: Mediceo CEO
July 31, 2015
- Nichi-Iko to Tie Up with Thai Drug Maker to Strengthen Lineup, Accelerate Brand Penetration
July 31, 2015
- Nippon Kayaku Initiates PIII Study of Herceptin Biosimilar in Japan
July 31, 2015
- Sumitomo Dainippon’s Leigh Syndrome Drug Showed No Statistical Difference in PIIb Study in US
July 31, 2015
- Cresemba Fails to Meet Primary Endpoint in PIII Study for Candidemia: Astellas
July 31, 2015
- Eisai Files Halaven for Soft Tissue Sarcoma Simultaneously in Japan, US, Europe
July 31, 2015
- Kyowa Kirin Files NDA for Brodalumab for Psoriasis in Japan
July 31, 2015
- Kyowa Kirin, BMS to Collaborate in Study of Combination Poteligeo, Opdivo in US
July 31, 2015
- AbbVie Pres. Says Japan Attracting Foreign Investments, Confident in Hep C Drug
July 31, 2015
- Delving into Securities Filings - 3: Sales Rep Ratio at Drug Makers Up Slightly in FY2014
July 31, 2015
- Series: Delving into Securities Filings
July 31, 2015
- ASCO Immunotherapy Roundup - 4: Merck KGaA Trailing Rivals with ADCC-Inducing Avelumab
July 30, 2015
- Takecab Maintains Top Position for 6th Month Running in HP Market in June: Anterio Ranking
July 30, 2015
- Lenvima Receives Breakthrough Therapy Designation from US FDA
July 30, 2015
- Rebetol Approved for Combination Use with Sovaldi for Genotype 2 Chronic Hepatitis C Virus Infection: MSD
July 30, 2015
- Teijin Pharma Files Feburic for Hyperuricemia in Patients Undergoing Chemotherapy in Japan
July 30, 2015
- Delving into Securities Filings - 2: Drug Maker Employees Decrease 0.9% in 5 Years
July 30, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…